Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Tongmai Jiangzhuo granules is a Traditional Chinese Medicine (TCM) herbal formulation developed by the Affiliated Hospital of Liaoning University of Traditional Chinese Medicine. It is primarily investigated for the early intervention of preclinical atherosclerosis. The formulation is designed to "unblock vessels" and "reduce turbidity," targeting cardiovascular risk factors and the progression of carotid intima-media thickness (CIMT). In clinical studies, it is evaluated as an adjunct to lifestyle interventions to improve cardiovascular outcomes and metabolic markers. It has been studied in Phase 3 clinical trials in China.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Tongmai Jiangzhuo granules.